Literature DB >> 31842540

Instructive Advances in Chemical Microbiology Inspired by Nature's Diverse Inventory of Molecules.

Ke Liu1, Robert W Huigens1.   

Abstract

Natural product antibiotics have played an essential role in the treatment of bacterial infection in addition to serving as useful tools to explore the intricate biology of bacteria. Our current arsenal of antibiotics operate through the inhibition of well-defined bacterial targets critical for replication and growth. Pathogenic bacteria effectively utilize a diversity of mechanisms that lead to acquired resistance and/or innate tolerance toward antibiotic therapies, which can result in devastating consequences to human life. Several research groups have established innovative programs that work at the chemistry-biology interface to develop new molecules that aim to define and address concerns related to antibiotic resistance and tolerance. In this Review, we present recent progress by select research groups that highlight a diversity of integrated chemical biology and medicinal chemistry approaches aimed at the development and utilization of chemical tools that have led to promising new microbiological insights that may lead to significant clinical advances regarding the treatment of pathogenic bacteria.

Entities:  

Keywords:  antibiotic discovery; antibiotic resistance; antibiotic tolerance; chemical biology; chemical microbiology; medicinal chemistry

Mesh:

Substances:

Year:  2020        PMID: 31842540      PMCID: PMC7346871          DOI: 10.1021/acsinfecdis.9b00413

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  112 in total

Review 1.  Mechanisms of antibiotic resistance in bacterial biofilms.

Authors:  Philip S Stewart
Journal:  Int J Med Microbiol       Date:  2002-07       Impact factor: 3.473

2.  Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I.

Authors:  Palaniappan Kulanthaivel; Adam J Kreuzman; Mark A Strege; Matthew D Belvo; Tim A Smitka; Matthew Clemens; James R Swartling; Kristina L Minton; Feng Zheng; Eddie L Angleton; Deborah Mullen; Louis N Jungheim; Valentine J Klimkowski; Thalia I Nicas; Richard C Thompson; Sheng-Bin Peng
Journal:  J Biol Chem       Date:  2004-06-01       Impact factor: 5.157

3.  N-Terminus Alkylation of Vancomycin: Ligand Binding Affinity, Antimicrobial Activity, and Site-Specific Nature of Quaternary Trimethylammonium Salt Modification.

Authors:  Zhi-Chen Wu; Nicholas A Isley; Dale L Boger
Journal:  ACS Infect Dis       Date:  2018-08-08       Impact factor: 5.084

4.  On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari.

Authors:  W P Hammes; F C Neuhaus
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

5.  Efficient NQO1 substrates are potent and selective anticancer agents.

Authors:  Elizabeth I Parkinson; Joseph S Bair; Megan Cismesia; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2013-08-22       Impact factor: 5.100

6.  The role of bacterial biofilms in chronic infections.

Authors:  Thomas Bjarnsholt
Journal:  APMIS Suppl       Date:  2013-05

7.  An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.

Authors:  Aaron T Garrison; Yasmeen Abouelhassan; Dimitris Kallifidas; Hao Tan; Young S Kim; Shouguang Jin; Hendrik Luesch; Robert W Huigens
Journal:  J Med Chem       Date:  2018-04-19       Impact factor: 7.446

8.  Optimized arylomycins are a new class of Gram-negative antibiotics.

Authors:  Peter A Smith; Michael F T Koehler; Hany S Girgis; Donghong Yan; Yongsheng Chen; Yuan Chen; James J Crawford; Matthew R Durk; Robert I Higuchi; Jing Kang; Jeremy Murray; Prasuna Paraselli; Summer Park; Wilson Phung; John G Quinn; Tucker C Roberts; Lionel Rougé; Jacob B Schwarz; Elizabeth Skippington; John Wai; Min Xu; Zhiyong Yu; Hua Zhang; Man-Wah Tan; Christopher E Heise
Journal:  Nature       Date:  2018-09-12       Impact factor: 49.962

9.  Total synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.

Authors:  Akinori Okano; Atsushi Nakayama; Alex W Schammel; Dale L Boger
Journal:  J Am Chem Soc       Date:  2014-09-16       Impact factor: 15.419

10.  Antibiotics: Combatting Tolerance To Stop Resistance.

Authors:  Etthel M Windels; Joran E Michiels; Bram Van den Bergh; Maarten Fauvart; Jan Michiels
Journal:  mBio       Date:  2019-09-10       Impact factor: 7.867

View more
  4 in total

1.  Modular Synthetic Routes to Fluorine-Containing Halogenated Phenazine and Acridine Agents That Induce Rapid Iron Starvation in Methicillin-Resistant Staphylococcus aureus Biofilms.

Authors:  Ke Liu; Massimiliano Brivio; Tao Xiao; Verrill M Norwood; Young S Kim; Shouguang Jin; Antonio Papagni; Luca Vaghi; Robert W Huigens
Journal:  ACS Infect Dis       Date:  2022-01-28       Impact factor: 5.084

2.  Progress towards a stable cephalosporin-halogenated phenazine conjugate for antibacterial prodrug applications.

Authors:  Tao Xiao; Ke Liu; Robert W Huigens
Journal:  Bioorg Med Chem Lett       Date:  2020-08-27       Impact factor: 2.823

3.  A Modular Synthetic Route Involving N-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.

Authors:  Hongfen Yang; Shivani Kundra; Michaelle Chojnacki; Ke Liu; Marisa A Fuse; Yasmeen Abouelhassan; Dimitris Kallifidas; Peilan Zhang; Guangtao Huang; Shouguang Jin; Yousong Ding; Hendrik Luesch; Kyle H Rohde; Paul M Dunman; José A Lemos; Robert W Huigens
Journal:  J Med Chem       Date:  2021-04-21       Impact factor: 8.039

4.  An ether-linked halogenated phenazine-quinone prodrug model for antibacterial applications.

Authors:  Robert W Huigens Iii; Hongfen Yang; Ke Liu; Young S Kim; Shouguang Jin
Journal:  Org Biomol Chem       Date:  2021-08-05       Impact factor: 3.890

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.